Analysts Anticipate Evelo Biosciences Inc (NASDAQ:EVLO) Will Post Earnings of -$0.67 Per Share
Equities analysts expect Evelo Biosciences Inc (NASDAQ:EVLO) to post earnings per share of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evelo Biosciences’ earnings. Evelo Biosciences posted earnings of ($0.50) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 34%. The firm is expected to report its next quarterly earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Evelo Biosciences will report full year earnings of ($2.46) per share for the current fiscal year, with EPS estimates ranging from ($2.65) to ($2.16). For the next year, analysts expect that the company will report earnings of ($1.97) per share, with EPS estimates ranging from ($2.15) to ($1.68). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Evelo Biosciences.
Evelo Biosciences (NASDAQ:EVLO) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.05).
Shares of NASDAQ EVLO traded up $1.14 during mid-day trading on Friday, hitting $7.89. 62,114 shares of the stock traded hands, compared to its average volume of 43,636. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.86 and a quick ratio of 11.86. Evelo Biosciences has a twelve month low of $4.90 and a twelve month high of $15.89. The company has a market cap of $216.40 million, a PE ratio of -2.84 and a beta of -0.22. The firm has a 50 day simple moving average of $6.22 and a two-hundred day simple moving average of $7.74.
Large investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new position in Evelo Biosciences during the 1st quarter worth $122,000. Deutsche Bank AG raised its position in Evelo Biosciences by 68.0% during the 4th quarter. Deutsche Bank AG now owns 18,048 shares of the company’s stock worth $234,000 after purchasing an additional 7,305 shares during the last quarter. FMR LLC raised its position in Evelo Biosciences by 0.6% during the 1st quarter. FMR LLC now owns 3,325,107 shares of the company’s stock worth $26,601,000 after purchasing an additional 19,100 shares during the last quarter. Morgan Stanley raised its position in Evelo Biosciences by 15.0% during the 2nd quarter. Morgan Stanley now owns 64,206 shares of the company’s stock worth $576,000 after purchasing an additional 8,366 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Evelo Biosciences by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 435,335 shares of the company’s stock worth $3,909,000 after purchasing an additional 3,685 shares during the last quarter. 86.20% of the stock is owned by institutional investors and hedge funds.
About Evelo Biosciences
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Read More: What is the Bid-Ask Spread?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.